Jefferies raised the firm’s price target on Denali Therapeutics (DNLI) to $45 from $40 and keeps a Buy rating on the shares ahead of the ...

In a report released today, Michael Yee from Jefferies maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a ...

On Friday, Denali Therapeutics Inc (DNLI) stock saw a modest uptick, ending the day at $27.05 which represents a slight increase of $1.09 or 4.20% from the prior close of $25.96. The stock opened at ...

On Monday, Denali Therapeutics Inc (DNLI) stock saw a modest uptick, ending the day at $27.78 which represents a slight increase of $1.63 or 6.23% from the prior close of $26.15. The stock opened at ...

Jefferies raised the firm’s price target on Denali Therapeutics (DNLI) to $45 from $40 and keeps a Buy rating on the shares ahead of the company reporting first DNL-126 Phase 1/2 data in ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Denali Therapeutics Inc. (DNLI) reports results for the quarter ended September 2024. While this widely-known ...

On Friday, Denali Therapeutics Inc. (NASDAQ: NASDAQ:DNLI) saw its price target increased by an analyst at Jefferies from $40.00 to $45.00 while the firm maintained a Buy rating on the stock.

Denali Therapeutics announces its Phase 2 study of oditrasertib was discontinued. Denali's strategic partner says the study failed to meet the primary and key secondary endpoints. Denali ...

Morgan Stanley (NYSE:MS) analyst Matthew Harrison maintained a Buy rating on Denali Therapeutics (NASDAQ:DNLI) Inc on Monday, setting a price target of $45, which is... H.C. Wainwright analyst ...

Oct 10 (Reuters) - Denali Therapeutics (DNLI.O), opens new tab said on Thursday its partner Sanofi (SASY.PA), opens new tab has discontinued a mid-stage study testing their experimental drug to ...